Australia markets closed

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
38.24+0.87 (+2.33%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 55.39B
Enterprise value 34.51B
Trailing P/E N/A
Forward P/E 1-22.10
PEG ratio (5-yr expected) 1-0.25
Price/sales (ttm)7.62
Price/book (mrq)7.92
Enterprise value/revenue 36.37
Enterprise value/EBITDA 7-29.99

Trading information

Stock price history

Beta (5Y monthly) 1.07
52-week change 3-30.50%
S&P500 52-week change 341.30%
52-week high 364.37
52-week low 335.10
50-day moving average 341.68
200-day moving average 350.96

Share statistics

Avg vol (3-month) 31.56M
Avg vol (10-day) 32.47M
Shares outstanding 5140.96M
Implied shares outstanding 6N/A
Float 134.06M
% held by insiders 14.86%
% held by institutions 190.12%
Shares short (29 Apr 2021) 410.31M
Short ratio (29 Apr 2021) 47.07
Short % of float (29 Apr 2021) 48.67%
Short % of shares outstanding (29 Apr 2021) 47.31%
Shares short (prior month 30 Mar 2021) 48.77M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021

Profitability

Profit margin -70.89%
Operating margin (ttm)-23.53%

Management effectiveness

Return on assets (ttm)-3.90%
Return on equity (ttm)-46.80%

Income statement

Revenue (ttm)707.5M
Revenue per share (ttm)5.06
Quarterly revenue growth (yoy)-16.30%
Gross profit (ttm)182.24M
EBITDA -150.31M
Net income avi to common (ttm)-501.73M
Diluted EPS (ttm)-3.59
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.82B
Total cash per share (mrq)12.93
Total debt (mrq)940.42M
Total debt/equity (mrq)138.18
Current ratio (mrq)6.74
Book value per share (mrq)4.83

Cash flow statement

Operating cash flow (ttm)-11.18M
Levered free cash flow (ttm)95.05M